Page last updated: 2024-10-19

nitrates and Vascular Diseases

nitrates has been researched along with Vascular Diseases in 39 studies

Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.

Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.

Research Excerpts

ExcerptRelevanceReference
"Nitric oxide (NO) is a potent vasodilator in the lung, whose bioavailability and signaling pathway are impaired in PAH."2.49Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics. ( Bueno, M; Gladwin, MT; Mora, AL; Wang, J, 2013)
"Nitrates have been commonly used in the therapy of cardiovascular disease for more than 150 years."2.47[Nitrates in cardiology: current role and areas of uncertainty]. ( Appignani, M; Bellisarii, FI; De Caterina, R; Muscente, F; Radico, F, 2011)
"Periodontitis was induced in mice by placement of a ligature for 14 days around the second molar."1.91Local delivery of nitric oxide prevents endothelial dysfunction in periodontitis. ( Ahluwalia, A; Barnes, MR; Curtis, M; D'Aiuto, F; Fernandes, D; Foster, J; Gee, LC; Goddard, A; Godec, T; Khambata, RS; Massimo, G; Orlandi, M; Ruivo, E; Wade, WG, 2023)
" Patients still presented high levels of interleukin (IL)-6, IL-8, and C-reactive protein, and low bioavailability of nitric oxide 7 days after the CABG surgery with CPB."1.40Post-operative endothelial dysfunction assessment using laser Doppler perfusion measurement in cardiac surgery patients. ( Gomes, MB; Gomes, V; Lessa, MA; Tibirica, E, 2014)
" Meanwhile, a most appropriate match of prescription dosage for curing vascular disease was got, which was based on NO value of pharmacodynamics experimental data and the endothelial cells configuration which would changed in a degree when damaged by hydration diamine."1.32A new experimental design for screening Chinese medicine formula. ( Bo-Chu, W; Chun-Hong, T; Li, Z; Qi, C; Shao-Xi, C, 2004)

Research

Studies (39)

TimeframeStudies, this research(%)All Research%
pre-19905 (12.82)18.7374
1990's5 (12.82)18.2507
2000's12 (30.77)29.6817
2010's11 (28.21)24.3611
2020's6 (15.38)2.80

Authors

AuthorsStudies
Morishima, T1
Iemitsu, M1
Fujie, S1
Ochi, E1
Namwong, A1
Kumphune, S1
Seenak, P1
Chotima, R1
Nernpermpisooth, N1
Malakul, W1
Fernandes, D1
Khambata, RS2
Massimo, G2
Ruivo, E1
Gee, LC1
Foster, J1
Goddard, A1
Curtis, M1
Barnes, MR1
Wade, WG1
Godec, T2
Orlandi, M1
D'Aiuto, F1
Ahluwalia, A2
Münzel, T3
Daiber, A3
Tawa, M1
Nakagawa, K1
Ohkita, M1
Shabbir, A1
Chhetri, I1
Parakaw, T1
Lau, C1
Aubdool, MABN1
Dyson, N1
Kapil, V1
Apea, V1
Flint, J1
Orkin, C1
Rathod, KS1
Majumdar, AS1
Joshi, PA1
Giri, PR1
Gomes, V1
Gomes, MB1
Tibirica, E1
Lessa, MA1
Steven, S1
Weaver, JL1
Snyder, R1
Knapton, A1
Herman, EH1
Honchel, R1
Miller, T1
Espandiari, P1
Smith, R1
Gu, YZ1
Goodsaid, FM1
Rosenblum, IY1
Sistare, FD1
Zhang, J1
Hanig, J1
Kaur, J1
Reddy, K1
Balakumar, P2
Gori, T1
Ude, M1
Ude, C1
Leuner, K1
Bellisarii, FI1
Muscente, F1
Radico, F1
Appignani, M1
De Caterina, R1
Gentner, NJ1
Weber, LP1
Alef, MJ1
Tzeng, E1
Zuckerbraun, BS1
Bueno, M1
Wang, J1
Mora, AL1
Gladwin, MT1
Kathuria, S1
Mahadevan, N1
Szabó, C1
Mabley, JG1
Moeller, SM1
Shimanovich, R1
Pacher, P1
Virag, L1
Soriano, FG1
Van Duzer, JH1
Williams, W1
Salzman, AL1
Groves, JT1
Moore, PK1
Marshall, M1
ABRAMSON, DI1
Migliacci, R1
Falcinelli, F1
Imperiali, P1
Floridi, A1
Nenci, GG1
Gresele, P1
Chun-Hong, T1
Bo-Chu, W1
Qi, C1
Li, Z1
Shao-Xi, C1
Szocs, K1
Meadows, GE1
Kotajima, F1
Vazir, A1
Kostikas, K1
Simonds, AK1
Morrell, MJ1
Corfield, DR1
Shah, DI1
Singh, M1
Lalu, MM1
Cena, J1
Chowdhury, R1
Lam, A1
Schulz, R1
Gayraud, M1
Harris, PJ1
Lee, KL1
Harrell, FE1
Behar, VS1
Rosati, RA1
Katusic, ZS1
Leopold, JA1
Loscalzo, J1
Carrizo, PH1
Dubin, M1
Stoppani, AO1
Thom, SR1
Ohnishi, ST1
Fisher, D1
Xu, YA1
Ischiropoulos, H1
Murohara, T1
Kugiyama, K1
Ota, Y1
Doi, H1
Ogata, N1
Ohgushi, M1
Yasue, H1
Price, DT1
Vita, JA1
Keaney, JF1
Ruschitzka, F1
Quaschning, T1
Noll, G1
deGottardi, A1
Rossier, MF1
Enseleit, F1
Hürlimann, D1
Lüscher, TF1
Shaw, SG1
Strano, A1
Novo, S1
Shub, C1
Vlietstra, RE1
McGoon, MD1
Novák, J1
Gavallér, L1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension[NCT01431313]Phase 248 participants (Actual)Interventional2012-06-30Completed
Effects of Oral Antioxidant Cocktail on Vascular Function and Blood Flow in Cardiovascular Disease Patients[NCT03629613]0 participants (Actual)Interventional2020-12-01Withdrawn (stopped due to discontinued due to change in operating plans prior to study initiation and enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Mitochondrial Oxygen Consumption Compared to Baseline After Each Dose of Nitrite

Basal platelet oxygen consumption measured in isolated platelets by extracellular flux analysis (XF24, Seahorse Biosciences, Billerica, MA). (NCT01431313)
Timeframe: Maximal effect at 15 minutes post 45mg or 90mg inhalation vs Pre dose

Interventionpicomoles O2/min (Mean)
WHO Group I Pulmonary Arterial Hypertension (PAH)-17.58
WHO Group II Pulmonary Hypertension (PH)8.62
WHO Group III Pulmonary Hypertension (PH)-11.64

Change in Plasma Nitrite Concentrations in Mixed Venous Blood

Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of plasma nitrite concentrations in mixed venous blood over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation

Interventionmicromolar (Mean)
WHO Group I Pulmonary Arterial Hypertension (PAH)9.9
WHO Group II Pulmonary Hypertension (PH)7.0
WHO Group III Pulmonary Hypertension (PH)7.4

Change in Pulmonary Artery Occlusion (Capillary) Pullback Nitrite

Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of pulmonary artery occlusion (capillary) pullback nitrite concentration over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation

Interventionmicromolar (Mean)
WHO Group I Pulmonary Arterial Hypertension (PAH)9.2
WHO Group III Pulmonary Hypertension (PH)2.4

Change in Pulmonary Vascular Impedance / Wave Intensity

Characteristic impedance (Zc) which may be related to compliance effects in the large, conduit arteries. (NCT01431313)
Timeframe: Pre dose and 60 minutes post last dosage inhaled

Interventiondyne*sec/cm5 (Median)
WHO Group I Pulmonary Arterial Hypertension (PAH)-0.004
WHO Group II Pulmonary Hypertension (PH)-0.34
WHO Group III Pulmonary Hypertension (PH)-0.20

Change in Pulmonary Vascular Resistance (PVR)

Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since pulmonary vascular resistance (PVR) was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of PVR over all subsequent times and doses (beta from the mixed effects model, converted back from natural log to Woods units), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose

InterventionWoods units (Mean)
WHO Group I Pulmonary Arterial Hypertension (PAH)0.77
WHO Group II Pulmonary Hypertension (PH)0.40
WHO Group III Pulmonary Hypertension (PH)-0.39

Change in Systemic Blood Pressure (Mean Arterial Pressure, MAP)

Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of MAP over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose

InterventionmmHg (Mean)
WHO Group I Pulmonary Arterial Hypertension (PAH)-5.1
WHO Group II Pulmonary Hypertension (PH)-3.4
WHO Group III Pulmonary Hypertension (PH)-9.5

Change in Systemic Vascular Resistance (SVR)

Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since systemic vascular resistance was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of SVR over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose

InterventionmmHg⋅min/L (Mean)
WHO Group I Pulmonary Arterial Hypertension (PAH)-0.43
WHO Group II Pulmonary Hypertension (PH)1.19
WHO Group III Pulmonary Hypertension (PH)-2.04

Time to Maximum Pulmonary Vascular Resistance (PVR) Decrease

Time in minutes to maximum PVR decrease. During study procedure, hemodynamics were measured at 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose. The time point at which each patient's maximal decrease in PVR occurred was recorded and reported as the mean and standard deviation in each cohort. (NCT01431313)
Timeframe: 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose

Interventionminutes (Mean)
WHO Group I Pulmonary Arterial Hypertension (PAH)42.0
WHO Group II Pulmonary Hypertension (PH)33.0
WHO Group III Pulmonary Hypertension (PH)42.5

Reviews

15 reviews available for nitrates and Vascular Diseases

ArticleYear
Vascular Redox Signaling, Endothelial Nitric Oxide Synthase Uncoupling, and Endothelial Dysfunction in the Setting of Transportation Noise Exposure or Chronic Treatment with Organic Nitrates.
    Antioxidants & redox signaling, 2023, Volume: 38, Issue:13-15

    Topics: Cardiovascular Diseases; Endothelium, Vascular; Humans; Nitrates; Nitric Oxide; Nitric Oxide Synthas

2023
Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction.
    Vascular pharmacology, 2014, Volume: 63, Issue:3

    Topics: Animals; Drug Tolerance; Endothelium, Vascular; Humans; Nitrates; Vascular Diseases; Vasodilation; V

2014
[Mechanisms and clinical significance of nitrate tolerance].
    Pharmazie in unserer Zeit, 2010, Volume: 39, Issue:5

    Topics: Aldehyde Dehydrogenase; Angina Pectoris; Animals; Drug Tolerance; Heart Failure; Humans; Nitrates; O

2010
[Nitrates and PDE5 inhibitors: pharmaceutical care].
    Pharmazie in unserer Zeit, 2010, Volume: 39, Issue:5

    Topics: Erectile Dysfunction; Humans; Male; Nitrates; Pharmaceutical Services; Pharmacies; Phosphodiesterase

2010
[Nitrates in cardiology: current role and areas of uncertainty].
    Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:1

    Topics: Cardiovascular Diseases; Drug Tolerance; Heart Failure; Humans; Myocardial Ischemia; Nitrates; Pract

2011
Nitric oxide and nitrite-based therapeutic opportunities in intimal hyperplasia.
    Nitric oxide : biology and chemistry, 2012, May-15, Volume: 26, Issue:4

    Topics: Animals; Humans; Hyperplasia; Nitrates; Nitric Oxide; Nitrites; Signal Transduction; Tunica Intima;

2012
Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics.
    Antioxidants & redox signaling, 2013, May-10, Volume: 18, Issue:14

    Topics: Animals; Humans; Hypertension, Pulmonary; Nitrates; Nitric Oxide; Nitrites; Signal Transduction; Vas

2013
Nitric oxide releasing acetaminophen (nitroacetaminophen).
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2003, Volume: 35 Suppl 2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease M

2003
Endothelial dysfunction and reactive oxygen species production in ischemia/reperfusion and nitrate tolerance.
    General physiology and biophysics, 2004, Volume: 23, Issue:3

    Topics: Animals; Antioxidants; Blood Vessels; Drug Tolerance; Endothelium, Vascular; Humans; Nitrates; Nitri

2004
Raynaud's phenomenon.
    Joint bone spine, 2007, Volume: 74, Issue:1

    Topics: Adrenergic alpha-Antagonists; Angiotensin Receptor Antagonists; Connective Tissue Diseases; Endocrin

2007
Superoxide anion and endothelial regulation of arterial tone.
    Free radical biology & medicine, 1996, Volume: 20, Issue:3

    Topics: Animals; Arteries; Endothelium, Vascular; Homeostasis; Humans; Models, Cardiovascular; Muscle Tonus;

1996
New developments in nitrosovasodilator therapy.
    Vascular medicine (London, England), 1997, Volume: 2, Issue:3

    Topics: Humans; Nitrates; Nitric Oxide; Vascular Diseases; Vasodilator Agents

1997
Redox control of vascular nitric oxide bioavailability.
    Antioxidants & redox signaling, 2000,Winter, Volume: 2, Issue:4

    Topics: Animals; Antioxidants; Biological Availability; Blood Vessels; Catalase; Glutathione Peroxidase; Hum

2000
[Calcium antagonists in cardiology].
    Bollettino della Societa italiana di cardiologia, 1978, Issue:1 Suppl

    Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium; Coronary Disease; Human

1978
Selection of optimal drug therapy for the patient with angina pectoris.
    Mayo Clinic proceedings, 1985, Volume: 60, Issue:8

    Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel

1985

Trials

2 trials available for nitrates and Vascular Diseases

ArticleYear
Prior beetroot juice ingestion offsets endothelial dysfunction following prolonged sitting.
    Journal of applied physiology (Bethesda, Md. : 1985), 2022, 07-01, Volume: 133, Issue:1

    Topics: Beta vulgaris; Blood Pressure; Dietary Supplements; Double-Blind Method; Eating; Female; Fruit and V

2022
A double-blind, randomised, placebo-controlled parallel study to investigate the effect of sex and dietary nitrate on COVID-19 vaccine-induced vascular dysfunction in healthy men and women: protocol of the DiNOVasc-COVID-19 study.
    Trials, 2023, Sep-16, Volume: 24, Issue:1

    Topics: COVID-19; COVID-19 Vaccines; Female; Humans; Male; Nitrates; Pulse Wave Analysis; Randomized Control

2023

Other Studies

22 other studies available for nitrates and Vascular Diseases

ArticleYear
Pineapple fruit improves vascular endothelial dysfunction, hepatic steatosis, and cholesterol metabolism in rats fed a high-cholesterol diet.
    Food & function, 2022, Oct-03, Volume: 13, Issue:19

    Topics: Ananas; Animals; Antioxidants; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Diet; Fatty Liver; Frui

2022
Local delivery of nitric oxide prevents endothelial dysfunction in periodontitis.
    Pharmacological research, 2023, Volume: 188

    Topics: Animals; Endothelium, Vascular; Mice; Nitrates; Nitric Oxide; Nitrites; Periodontitis; Vascular Dise

2023
Effects of beetroot juice supplementation on vascular functional and structural changes in aged mice.
    Physiological reports, 2023, Volume: 11, Issue:12

    Topics: Acetylcholine; Animals; Antioxidants; Dietary Supplements; Mice; Nitrates; Vascular Diseases

2023
Resveratrol attenuated smokeless tobacco-induced vascular and metabolic complications in ovariectomized rats.
    Menopause (New York, N.Y.), 2013, Volume: 20, Issue:8

    Topics: Animals; Aorta; Collagen; Diabetes Complications; Diabetes Mellitus; Estradiol; Female; Glucose Tole

2013
Post-operative endothelial dysfunction assessment using laser Doppler perfusion measurement in cardiac surgery patients.
    Acta anaesthesiologica Scandinavica, 2014, Volume: 58, Issue:4

    Topics: Acetylcholine; Capillaries; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Byp

2014
Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 534385.
    Toxicologic pathology, 2008, Volume: 36, Issue:6

    Topics: Animals; Biomarkers; Blood Vessels; Clinical Chemistry Tests; Cyclic N-Oxides; Dose-Response Relatio

2008
The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat.
    Cardiovascular toxicology, 2010, Volume: 10, Issue:3

    Topics: Animals; Arsenites; Cholesterol; Endothelium, Vascular; Fenofibrate; Hypolipidemic Agents; In Vitro

2010
Secondhand tobacco smoke, arterial stiffness, and altered circadian blood pressure patterns are associated with lung inflammation and oxidative stress in rats.
    American journal of physiology. Heart and circulatory physiology, 2012, Feb-01, Volume: 302, Issue:3

    Topics: Animals; Blood Pressure; Circadian Rhythm; Endothelium, Vascular; Male; Nitrates; Nitric Oxide; Nitr

2012
Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.
    Molecular and cellular biochemistry, 2013, Volume: 374, Issue:1-2

    Topics: Anilides; Animals; Endothelium, Vascular; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductas

2013
Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst.
    Molecular medicine (Cambridge, Mass.), 2002, Volume: 8, Issue:10

    Topics: Animals; Catalysis; Cytoprotection; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Re

2002
DRUGS USED IN PERIPHERAL VASCULAR DISEASES.
    The American journal of cardiology, 1963, Volume: 12

    Topics: Deoxyribonuclease I; Dihydroergotoxine; Endopeptidases; Ergot Alkaloids; Ganglionic Blockers; Histam

1963
Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis.
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2004, Volume: 5, Issue:5

    Topics: Adult; Aged; Biomarkers; Blood Pressure; Cyclic GMP; Diastole; Endothelium, Vascular; Female; Homocy

2004
A new experimental design for screening Chinese medicine formula.
    Colloids and surfaces. B, Biointerfaces, 2004, Jul-15, Volume: 36, Issue:2

    Topics: Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drugs, Chinese Herb

2004
Overnight changes in the cerebral vascular response to isocapnic hypoxia and hypercapnia in healthy humans: protection against stroke.
    Stroke, 2005, Volume: 36, Issue:11

    Topics: Adult; Brain; Cerebrovascular Circulation; Humans; Hypercapnia; Hypoxia; Ischemia; Male; Middle Cere

2005
Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction.
    Naunyn-Schmiedeberg's archives of pharmacology, 2006, Volume: 373, Issue:3

    Topics: Animals; Blood Pressure; Endothelins; Lipid Metabolism; Male; Microscopy, Electron, Scanning; Nitrat

2006
Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction.
    British journal of pharmacology, 2006, Volume: 149, Issue:1

    Topics: Animals; Aorta, Thoracic; Blotting, Western; Collagenases; Endotoxemia; Endotoxins; Gelatinases; In

2006
Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death.
    Circulation, 1980, Volume: 62, Issue:4

    Topics: Adrenergic beta-Antagonists; Cardiac Catheterization; Cardiovascular Diseases; Coronary Disease; Hea

1980
[Physiopathologic effects of nitric oxide and their relationship with oxidative stress].
    Medicina, 1998, Volume: 58, Issue:4

    Topics: Antioxidants; Humans; Liver Transplantation; Neoplasms; Neurodegenerative Diseases; Nitrates; Nitric

1998
Pulmonary vascular stress from carbon monoxide.
    Toxicology and applied pharmacology, 1999, Jan-01, Volume: 154, Issue:1

    Topics: Animals; Capillaries; Carbon Monoxide; Electron Spin Resonance Spectroscopy; Enzyme Inhibitors; Hydr

1999
Effects of atrial and brain natriuretic peptides on lysophosphatidylcholine-mediated endothelial dysfunction.
    Journal of cardiovascular pharmacology, 1999, Volume: 34, Issue:6

    Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Atrial Natriuretic Factor; Cattle; Coronary Vessels

1999
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
    Circulation, 2001, Jun-26, Volume: 103, Issue:25

    Topics: 11-beta-Hydroxysteroid Dehydrogenases; Acetylcholine; Animals; Blood Pressure; Body Weight; Cells, C

2001
[The effect of bencyclane on burns and other functional vascular disorders].
    Arzneimittel-Forschung, 1970, Volume: 20, Issue:10

    Topics: Blood Circulation; Burns; Cycloheptanes; Ethanolamines; Fumarates; Humans; Leg; Nitrates; Oscillomet

1970